Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adjuvanted hepatitis B vaccine HB-AS02V
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adjuvanted hepatitis B vaccine HB-AS02V is an investigational vaccine designed to induce protective immunity against hepatitis B virus (HBV), particularly in patients with renal insufficiency and other immunocompromised individuals who often have suboptimal responses to conventional recombinant HBV vaccines. It contains recombinant hepatitis B surface antigen (HBsAg) combined with the AS02 adjuvant system, which is an oil-in-water emulsion that includes monophosphoryl lipid A (MPL; a detoxified derivative of *Salmonella minnesota* lipopolysaccharide) and QS21 (an immunostimulant derived from *Quillaja saponaria* tree bark). The AS02 adjuvant system acts synergistically to stimulate both humoral and cellular (CD4+ Th1) immune responses, producing higher and more persistent anti-HBs antibody levels and T cell responses than standard non-adjuvanted or aluminum-based adjuvant HBV vaccines. HB-AS02V has demonstrated lot-to-lot manufacturing consistency, strong immunogenicity, and favorable safety profiles in clinical trials involving healthy adults and patients with renal insufficiency[1].
- Brand names
- Henogen HB vaccine
- Other names
- investigational adjuvanted hepatitis B vaccine HB-AS02
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on adjuvanted hepatitis B vaccine HB-AS02V.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adjuvanted hepatitis B vaccine HB-AS02V.